On Friday, Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI) saw its price target increased by an analyst at Jefferies from $40.00 to $45.00 while the firm maintained a Buy rating on the stock. The adjustment comes with expectations set on the biotechnology company's progress with its drug candidates and regulatory pathways.
Denali is anticipated to release Phase I/II data for its DNL-126 drug, aimed at treating Sanfilippo Type A, by the end of 2024. This drug is based on the same Enzyme Transport Vehicle (ETV) platform as Denali's lead candidate, DNL-310, which is currently in the process of FDA filing following positive data. The analyst notes that, like DNL-310, DNL-126 has secured the FDA's START orphan designation, potentially paving the way for expedited regulatory discussions.
The optimism is further supported by the potential for DNL-126 to benefit from a swift FDA approval path, similar to other orphan drugs. The START designation is particularly significant as it is granted to therapies that show promise in treating rare diseases, which could lead to faster development and review times by the FDA.
The analyst highlighted that strong and robust biomarker data, along with a good safety profile for the treatment of Sanfilippo, should help in de-risking the development of what could be Denali's second potential drug. The increase in the price target to $45 reflects the positive outlook and confidence in the drug's prospects.
Denali Therapeutics continues to focus on leveraging its ETV platform to develop treatments for neurodegenerative diseases, with the latest developments and regulatory designations marking important milestones in the company's journey towards bringing new therapies to market.
In other recent news, Denali Therapeutics has been the focus of several analyst firms following significant developments in its drug programs. BTIG maintained a Buy rating on Denali, acknowledging the failure of DNL788 in ALS and shifting attention to the remaining small molecule programs, particularly DNL343 and DNL151. The firm's investment thesis for Denali has been centered on its Transport Vehicle (TV) platform technology, designed to deliver biological payloads across the blood-brain barrier.
TD Cowen also maintained its Buy rating on Denali, despite a phase 2 study evaluating DNL788 not meeting its primary endpoint. The firm's outlook on Denali's TV platform remains unchanged, emphasizing its potential in addressing neurological diseases.
Denali's K2 Phase 2 study of oditrasertib for multiple sclerosis was terminated due to failure to meet primary and key secondary endpoints. However, the company has made strides with the FDA concerning their therapy for Hunter syndrome, tividenofusp alfa (DNL310), expected to file a Biologics License Application under an accelerated approval pathway in 2025.
BofA Securities increased its price target for Denali to $29 while maintaining a Buy rating, following progress with the FDA regarding its therapy for Hunter syndrome. B. Riley maintained a Buy rating and a $33.00 price target on Denali's shares following the FDA's favorable response regarding the accelerated approval pathway for DNL310.
Denali Therapeutics continues to show progress in its drug development programs, with several analyst firms maintaining a positive outlook on the company's stock.
InvestingPro Insights
As Denali Therapeutics Inc. (NASDAQ: DNLI) continues to make strides in its drug development pipeline, InvestingPro data provides additional context to the company's financial position. Despite the optimistic outlook from Jefferies analysts, it's important to note that Denali's revenue for the last twelve months as of Q2 2024 stood at just 1.27 million USD, with a significant revenue decline of -99.63% over the same period.
InvestingPro Tips highlight that Denali "holds more cash than debt on its balance sheet" and "liquid assets exceed short term obligations," which could be crucial for funding ongoing research and development efforts, especially given the company's current unprofitable status. This financial stability aligns with the company's need for sustained investment in its promising drug candidates like DNL-126 and DNL-310.
Another relevant InvestingPro Tip indicates a "large price uptick over the last six months," which is reflected in the 60.64% price total return over the past six months. This market performance suggests investor confidence in Denali's potential, possibly driven by the positive developments in its drug pipeline and regulatory progress mentioned in the article.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips that could provide further insights into Denali Therapeutics' financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.